Lansen Pharmaceutical Holdings Co. Ltd. announced at the AGM held on May 15, 2013, the shareholders approved final dividend of 10.20 Hong Kong cents per share of $0.01 each in the capital of the company out of the company's share premium account for the year ended 31 December 2012.

Lansen Pharmaceutical Holdings Co., Ltd, Annual General Meeting, May 15, 2013., at 15:00 China Standard Time. Location: London Room, 3/F., Nexxus Building. Agenda: To receive and consider the audited consolidated financial statements, the report of the directors and the independent auditor 's report thereon for the year ended 31 December 2012; to approve the recommended final dividend of HK 10.20 cents per share of USD 0.01 each in the capital of the company out of the company's share premium account for the year ended 31 December 2012; to re-elect Liu Bang Min and Stephen Burnau Hunt as executive Directors; to re-elect Lee Jin Yi and Tang Jun as non-executive Director; to re-appoint BDO Limited as the auditor of the company and to authorize the Board to fix its remuneration; and to grant a general mandate to the Directors to allot, issue and deal with additional shares not exceeding 20% of the issued share capital of the company as at the date of passing this resolution.

Lansen Pharmaceutical Holdings Co. Ltd. announced audited consolidated earnings results for the year ended December 31, 2012. For the year, the company’s revenue was $93,844,000 compared to $74,475,000 for the same period in 2011. Profit before income tax was $16,566,000 compared to $15,148,000 for the same period in 2011. Profit from operations was $16,169,000 compared to $13,666,000 for the same period in 2011. Profit attributable to owners of the company was $13,998,000 or 3.4 cents per basic share compared to $12,453,000 or 3.0 cents per basic share for the same period in 2011. Capital expenditure contracted for but not provided in the financial statements amounted to $2.6 million compared to $5.2 million for the same period in 2011. It was primarily due to the stable growth of the three core rheumatic specialty prescription products. Mainly for enhancing product awareness and market recognition of the core products. On 27 March 2013, the Board recommended that subject to Shareholders' approval in the forthcoming Annual General Meeting, the company shall declare and distribute a final dividend of 10.20 Hong Kong cents per share for the year ended 31 December 2012 to those Shareholders whose names appear on the register of members of the company at the close of business on 31 May 2013. Shareholders whose names appear of the register of members of the company on 31 May 2013 will be entitled to the final dividend, which, if approved, will be paid on or around 28 June 2013.